Medable unveils oncology trial platform aimed at reducing logistical hurdles
Ella Day | May 16, 2025 | News story | Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy | AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials
Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational complexity and improving data collection processes.
Oncology trials have become increasingly complex due to the rise of biomarker-guided research, advanced precision medicine and the demand for broader patient representation. These factors have contributed to challenges in trial design, recruitment and data monitoring.
Medable’s platform incorporates artificial intelligence, automation and electronic clinical outcome assessment tools including electronic patient-reported outcomes. It is intended to facilitate remote data collection, improve workflow efficiency and reduce the need for in-person site visits that could benefit patients experiencing fatigue or immunosuppression.
“The platform is specifically designed to address the biggest challenges in oncology trials, reducing complexity to speed [up] processes with less burden on sites and greater clarity for researchers,” said Musaddiq Khan, vice president of customer value and oncology lead at Medable.
The platform also includes protocol libraries and configurable workflows. It aligns with recent guidance from the US Food and Drug Administration supporting the digital capture of patient-reported outcomes in cancer research.
Medable reports that the platform is already in use across all four phases of oncology trials with over one million patients in 70 countries and 120 languages.
The company will present details of the new platform at the 2025 American Society of Clinical Oncology Annual Meeting between 30 May and 3 June in Chicago, US.
Ella Day
16/5/25
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
